Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis

Abstract

IntroductionTo examine whether aripiprazole once-monthly (AOM) was more beneficial than oral aripiprazole (OARI) in the treatment of adults with schizophrenia during the maintenance phase.

MethodsWe performed a systematic review and network meta-analysis of double-blind, randomized controlled trials that included two of the following treatments: AOM, OARI, and placebo.

ResultsWe identified four studies involving 1830 adults. Relapse rates at 26 weeks were lower for both AOM (odds ratio [OR] 0.240, 95% confidence interval [CI] 0.169–0.341) and OARI (OR=0.306, 95%CI=0.217–0.431) than for placebo, although their treatment outcomes did not differ significantly (OR=0.786, 95%CI=0.529–1.168). Rates of all-cause discontinuation were also lower with AOM (OR=0.300, 95% CI=0.227–0.396) and OARI (OR=0.441, 95%CI=0.333–0.582) than with placebo. The rate of all-cause discontinuation was lower with AOM than with OARI (OR=0.681, 95% CI=0.529–0.877)]. Other outcomes did not differ significantly between AOM and OARI.

DiscussionAlthough both AOM and OARI were efficacious in the treatment of schizophrenia during the maintenance phase, AOM was better accepted than OARI.

Key words

aripiprazole once-monthly - oral aripiprazole - schizophrenia in the maintenance phase: relapse, - all-cause discontinuation

Publication History

Received: 23 March 2022
Received: 29 April 2022

Accepted: 07 May 2022

Article published online:
05 July 2022

• References

• 1 Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet 2022; 399: 473-486
• 2 APA. The American Psychiatric Association Practice Guideline For The Treatment Of Patients With Schizophrenia: Third Edition. 2020
• 3 Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry 2019; 80
• 4 Kane JM, McEvoy JP, Correll CU. et al. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs 2021; 35: 1189-1205
• 5 Kishimoto T, Hagi K, Kurokawa S. et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8: 387-404
• 6 Ostuzzi G, Bertolini F, Del Giovane C. et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: A network meta-analysis. Am J Psychiatry 2021; 178: 424-436
• 7 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939-951
• 8 Pillinger T, McCutcheon RA, Vano L. et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64-77
• 9 Hutton B, Salanti G, Caldwell DM. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-784
• 10 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials 1986; 7: 177-188
• 11 Rücker G, Schwarzer G, Krahn U. et al. netmeta: Network meta-analysis using frequentist methods (R package version 0.9-5). https://CRANR-projectorg/package=netmeta 2017
• 12 Dias S, Welton NJ, Caldwell DM. et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29: 932-944
• 13 Jackson D, Barrett JK, Rice S. et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med 2014; 33: 3639-3654
• 14 Higgins J, Thomas J, Chandler J. et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). 2021
• 15 Pigott TA, Carson WH, Saha AR. et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056
• 16 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
• 17 Fleischhacker WW, Sanchez R, Perry PP. et al. Aripiprazole once-monthly for treatment of schizophrenia: Double-blind, randomised, non-inferiority study. Br J Psychiatry 2014; 205: 135-144
• 18 Salanti G, Del Giovane C, Chaimani A. et al. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE 2014; 9: e99682
• 19 Nikolakopoulou A, Higgins JPT, Papakonstantinou T. et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med 2020; 17: e1003082
• 20 Papakonstantinou T, Nikolakopoulou A, Higgins JPT. et al. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Systematic Reviews 2020; 16: e1080
• 21 Kane JM, Sanchez R, Perry PP. et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73: 617-624
• 22 Ishigooka J, Nakamura J, Fujii Y. et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res 2015; 161: 421-428
• 23 WHO. Defined Daily Dose (DDD) https://wwwwhoint/medicines/regulation/medicines-safety/toolkit_ddd/en/
• 24 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
• 25 Haddad PM, Kishimoto T, Correll CU. et al. Ambiguous findings concerning potential advantages of depot antipsychotics: In search of clinical relevance. Curr Opin Psychiatry 2015; 28: 216-221
• 26 Higgins J, Thomas J, Chandler J. et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. wwwtrainingcochraneorg/handbook. 2019